London, UK – Excellere Partners (“Excellere”), a Denver-based private equity firm specialising in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical (“Biocare”), a global leader in immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH) solutions, to Agilent Technologies, Inc. (“Agilent”, NYSE:A).
Under the stewardship of Excellere and GHO, the company delivered annual double-digit revenue and profitability growth, strengthened its core IHC business, expanded into molecular diagnostics through acquisition, and reinforced its executive leadership team. Biocare has since become a recognised specialist in IHC, ISH and FISH, with a high-quality antibody business and strong commercial, regulatory and R&D capabilities.
Agilent’s acquisition of Biocare brings together two businesses with closely aligned strategies in life sciences and diagnostics. The combination is expected to unlock greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.
In a joint statement, Excellere and GHO said: “This transaction marks a significant milestone for Biocare and a strong outcome for our portfolios. Working closely with Luis and the management team, we applied our growth playbook and deep sector expertise, to help build a company with genuine transatlantic reach and a leading position in IHC solutions. We are delighted to have found the right partner in Agilent to support Biocare’s next phase of growth and are confident that its global reach and resources will deliver even greater value for customers and, ultimately, the patients they serve.”
